Cipla is launching the COVID anti-viral medicine, molnupiravir, in South Africa.
This medication is for the treatment of mild-to-moderate COVID-19 in adults.
Caring for Life
As part of its ethos of “Caring for Life”, Cipla is once again championing equitable access to medication, much like it did during the height of the HIV pandemic, when it made life-saving antiretrovirals available at t less than $1 per day compared to over $12 000 per patient per year prevailing.
In line with its “Africa for Africa” strategy, Cipla is focused on supporting supply thanks to large-scale WHO- and SAHPRA-approved local manufacturing at its facilities in South Africa and in Uganda. Cipla also has a solid distribution chain in place to ensure that treatment can reach pharmacies and COVID-19 treatment centres across the country as quickly and efficiently as possible. Cipla will expand supply to several sub-Saharan African countries including Kenya, Uganda and Mauritius, and are exploring possibilities to export to in other markets too.
Good health for everyone
CEO of Cipla South Africa, Paul Miller, says: “Our mission has always been to remedy the disparity in access to high-quality, life-saving medicine, as we see a future where good health is expected not for the few but for everyone. This need is more prevalent than ever during the pandemic. This launch is a testament to our continued commitment to help find a solution in the fight against this unprecedented global pandemic.”
“We will work closely will all the relevant stakeholders to ensure that we can make this solution available in the local market as soon as possible,” says Miller. Cipla has a non-exclusive voluntary licensing agreement with the originator to manufacture and supply molnupiravir and is currently busy pursuing regulatory approvals to ensure equitable access.
Molnupiravir is an oral anti-viral that inhibits the replication of multiple ribonucleic acid (RNA) viruses including SARS-CoV-2. The drug is used for the treatment of non-hospitalised patients with confirmed COVID-19 globally.